TELA — TELA Bio, Inc.

TELA Bio, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $20.9 million, an 18% increase year-over-year.
• Full Year Revenue: $80.3 million, a 16% increase from 2024.
• OviTex Revenue Growth: 12% for the year; OviTex unit sales grew 20% in Q4.
• PRS Revenue Growth: 20% for the year; PRS unit sales grew 12% in Q4.
• LiquiFix Revenue: More than tripled over 2024, indicating strong early traction.
• Gross Margin: 66% in Q4 and 68% for the full year, up from 64% and 67% respectively.
• Operating Loss: $6.6 million in Q4 and $33.8 million for the full year, slightly improved from the prior year.
• Net Loss: $9.0 million in Q4 and $38.8 million for the full year, compared to $9.2 million and $37.8 million in the prior year.

2. Strategic Updates and Business Highlights

• Commercial Rebuild: Significant changes were made to the commercial organization, including a new sales leadership structure and recruitment of high-caliber sales reps, with 40% of the sales force being new hires.
• Product Innovations: Launched OviTex LTR and enrolled patients in the hiatal hernia trial ECHO, enhancing the clinical evidence base.
• European Market Performance: European sales grew 17% to $12.1 million, driven by strong adoption in the U.K. and The Netherlands.
• New CMO Appointment: Dr. Howard Lang was promoted to Chief Medical Officer to enhance engagement with the surgical community.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Anticipated growth of at least 8% over 2025, with Q1 2026 revenue expected to be approximately $18.5 million.
• Sales Strategy: Focus on deeper penetration in existing accounts and leveraging the full product portfolio to drive growth.
• Operational Improvements: Expecting a decline in operating and net losses throughout 2026 as new sales reps ramp up productivity.

4. Bad News, Challenges, or Points of Concern

• Prudence in Guidance: The revenue guidance was lowered from an earlier expectation of ~15% growth due to the complexity of integrating new sales reps and executing contracts.
• Q1 Challenges: Anticipated lower Q1 revenue due to seasonal market lulls and the impact of weather events affecting elective procedures.
• Contract Execution: Challenges in translating signed contracts into actual sales, with a focus on improving execution in 2026.
• Sales Force Disruption: The transition and restructuring of the sales team may temporarily hinder productivity.

5. Notable Q&A Insights

• Guidance Adjustments: Management emphasized the need for prudence in guidance due to the extensive changes made in the organization and the ramp-up time required for new hires.
• Market Dynamics: The sales team is focusing on deeper relationships with multiple surgeons within hospitals to improve product stickiness and mitigate risks from competitive pressures.
• Impact of External Factors: Weather and seasonal trends were noted as impacting Q1 performance, but management remains optimistic about recovery and growth in subsequent quarters.
• Long-term Growth Potential: Management expressed confidence in returning to double-digit growth rates in the future, driven by strong product demand and improved sales strategies.

Overall, TELA Bio, Inc. demonstrated resilience in revenue growth amidst significant organizational changes, with a cautious but optimistic outlook for 2026.